Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Micromet Investor Calls Amgen’s $1 Billion Bid Too Low

Micromet Inc. was sued by a shareholder who said Amgen Inc.’s $1 billion takeover offer for the drugmaker undervalues his stock.

Micromet’s board failed in its duty to get the best price, the investor, Bernard Passes, said in a complaint filed yesterday in Delaware Chancery Court in Wilmington. Amgen, based in Thousand Oaks, California, announced a deal on Jan. 26 to buy Micromet for $11 a share to gain an experimental leukemia drug.

“Given the company’s growth prospects and potential for significant income,” the transaction is inadequate, Passes said in his complaint. He said Micromet stock is worth at least $12 a share

Jennifer Neiman, a spokeswoman for Rockville, Maryland-based Micromet, declined to comment on the lawsuit.

Micromet, which closed at $8.28 the day before the takeover was announced, fell 1 cent to $10.95 at 12:04 p.m. New York time in Nasdaq Stock Market trading. Amgen, the world’s largest biotechnology company, declined 31 cents to $68.02.

The case is Passes v. Micromet, CA7198, Delaware Chancery Court (Wilmington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.